Medical billing and coding El Paso TX As of October 6, 2021, more than 65 percent of the United States’ population has received at least one dose of an existing COVID-19 vaccine, and more than 56 percent have been fully vaccinated, according to the Centers for Disease Control and Prevention. But as new variants of COVID-19 continue to emerge around the world, the effectiveness of vaccines and uncertainty surrounding the length of immunity have Americans on edge.


According to The New York Times newsletter, “The Morning,” published on October 4, 2021, “The share of Americans 12 and over who have received at least one vaccine shot has reached 76 percent, and the growing number of vaccine mandates — along with the likely authorization of the Pfizer vaccine for children ages 5 to 11 — will increase the number of vaccinations this fall. Almost as important, something like one-half of Americans have probably had the Covid virus already, giving them some natural immunity.” This data suggests that immunity eventually will become widespread enough “that another wave as large and damaging as the Delta wave will not be possible.” But in the meantime, medical researchers and other scientists have been exploring other possible treatments. Pharmaceutical companies have been in the process of research and development of the first oral antiviral to specifically target COVID-19.


Medical billing and coding El Paso TX According to reports from drug manufacturers, they are close to presenting several oral antiviral formulations for assessment by the U.S. Food and Drug Administration (FDA) under emergency use authorization as a new treatment for COVID-19 patients. Merck & Co. is currently seeking federal approval for emergency use of its new antiviral pill (called molnupiravir), after their clinical trial showed it to halve the risk of hospitalization or death when given to high-risk patients shortly after COVID-19 infection. This new treatment, developed by Merck in partnership with Ridgeback Biotherapeutics, works by introducing genetic errors into the virus and preventing it from being able to replicate the virus’s genetic material; it is designed to accomplish this by inserting critical errors into the genetic code. The pills are designed to be taken as soon as a person shows symptoms of having COVID-19, and continued over a five-day period, to potentially limit the impact of the infection and possibly keep people infected with COVID out of the hospital. A further possibility is the prevention of contracting the coronavirus by those in close proximity to infected individuals, such as caregivers and other family members.

Quick Claimers Medical Billing is a professional medical coding and billing company based in El Paso, Texas. Quick Claimers Medical Billing is committed to providing effective medical coding and billing solutions to healthcare professionals to support productivity and payment, especially as the COVID-19 pandemic persists. The capable and experienced team of medical coding and billing specialists at Quick Claimers will organize and process the healthcare claims for your practice with accuracy and efficiency, to ensure that you receive appropriate payment for all the services you provide. If you would like more information about the services offered, please contact Quick Claimers Medical Billing online or by phone at 915-351-6600.